[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-stromal-tumor-gist\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-stromal-tumor-gist":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,70,102,127,153,177,199,227,253,275],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054129","lrg-gist-patient-registry-100054129",false,"NCT07697248","LRG GIST Patient Registry","Life Raft Group GIST Registry Protocol","Inclusion Criteria:\n\n1. Gastrointestinal Stromal Tumor diagnosis\n2. Provide written and informed consent\n\nExclusion Criteria:\n\n\\-","ALL",{"count":18,"type":19},5000,"ESTIMATED","25 Years","OBSERVATIONAL","The Life Raft Group (LRG) Patient Registry is a structured database that collects comprehensive information about individuals diagnosed with GIST. The purpose of this registry is to facilitate research, improve understanding of the disease, track patient outcomes, and ultimately enhance patient care.",[24,25,26],"GIST","GIST - Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor (GIST)",[24],"RECRUITING","2026-07-08",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2013-04",{"date":36,"type":19},"2099-12-31",{"name":38,"class":39},"The Life Raft Group","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":40},"100644797","clinical-utility-of-ctdna-in-detecting-resistance-mechanisms-and-delivering-precision-medicine-to-cancer-patients-100644797","NCT07673861","Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients","Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine: A Tumour Agnostic Study","CURTAIN","Inclusion Criteria\n\nAll cohorts:\n\n* Age ≥18 years old\n* Ability to provide written informed consent\n* Presence of metastatic or unresectable disease\n* Being reviewed and treated through medical oncology service at Royal Marsden Hospital\n\nCohort 1: Locally Advanced\u002FMetastatic NSCLC\n\n* Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR\u002FALK\u002FROS1\u002FRET\u002FMET\u002FBRAF\u002FNTRK\u002FHER2\u002FKRAS), AND\n* Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent\n\nCohort 2: Locally Advanced\u002FMetastatic GIST\n\n* Locally advanced\u002Fmetastatic gastrointestinal stromal tumour (GIST), AND\n* Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent\n\nCohort 3: Metastatic Colorectal Cancer\n\n• Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND\n\n* If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent\n* If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +\u002F- an anti-EGFR agent within the 6 weeks prior to consent\n\nCohort 4: Locally Advanced\u002FMetastatic BTC\n\n* Identified targetable mutation (IDH1 mutation\u002FHER2 amplification\u002FFGFR2 fusion or rearrangement\u002FNTRK fusion\u002FBRAF V600E mutation\u002FMMR deficiency \\[dMMR\\]), AND\n* Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent\n\nCohort 5: Advanced\u002FMetastatic ovarian cancer\n\n* Diagnosis of advanced\u002Fmetastatic high-grade ovarian cancer, AND\n* Known BRCA status, AND\n* Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent\n\nExclusion Criteria\n\nAll cohorts:\n\n* Medically unstable to commit to sampling required for the study\n* ECOG performance status ≥3","18 Years",{"count":51,"type":19},100,"INTERVENTIONAL",[54],"NA","ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease).\n\nThe aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK).\n\nOne hundred patients will be recruited, with 20 from each of the following cancer types:\n\n* Non-small cell lung cancer\n* Gastrointestinal stromal tumours\n* Colorectal cancer\n* Biliary tract cancer\n* Ovarian cancer.\n\nPatients must be aged 18 or over, must have had progressive disease whilst receiving anti-cancer treatment, and must be being treated at The Royal Marsden.\n\nPatients will have a blood sample taken and analysed using the Marsden360 ctDNA test. The results of the test will be looked at by The Royal Marsden Genomic Tissue Advisory Board (GTAB), and for each individual patient, the GTAB will determine if having a ctDNA test helped to personalise their care by:\n\n* Aiding the identification of a genomically-matched standard of care therapy\n* Aiding the identification of a genomically-matched clinical trial (based in the UK)\n* Offering additional prognostic information not otherwise available through standard of care testing\n* Negating the need for a tissue biopsy.",[57,26,58,59,60],"Non Small Cell Lung Cancer","Colorectal Cancer","Biliary Tract Cancer","Ovarian Cancer","2026-06-24",{"date":63,"type":32},"2026-06-29",{"date":65,"type":32},"2025-05-23",{"date":67,"type":19},"2026-12-31",{"name":69,"class":39},"Royal Marsden NHS Foundation Trust",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100405330","surgery-in-gastrointestinal-stromal-tumors-gists-for-treatment-tumor-modeling-and-genomic-analysis-100405330","NCT04557969","Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","* INCLUSION CRITERIA:\n* Histological confirmation or clinical presentation suspicious of GIST; histological confirmation will be preferably by review of archival tissue if available, fresh biopsy will not be required if inadequate tissue sample.\n* Age \\>= 6 years\n* ECOG performance status \\\u003C= 2 (Karnofsky or Lansky \\>= 60%)\n* Ability of participant or parent\u002Fguardian to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n\\- Non-modifiable medical comorbidities that would preclude cytoreductive surgery.","6 Years",{"count":79,"type":19},400,"Objective:\n\nTo follow people with GISTs and collect tumor tissue so that it can be studied in the lab.\n\nEligibility:\n\nPeople age 6 and older who have a GIST.\n\nDesign:\n\nParticipants will be screened with a review of their medical records and samples.\n\nParticipants will enroll in 1 other NIH study, and may be asked to enroll in 2 other optional NIH studies.\n\nParticipants will have a medical history and physical exam. Data about how they function in their daily activities will be obtained.\n\nParticipants may speak with a genetic counselor. They may have genetic testing.\n\nParticipants will give blood samples. They may have a cheek swab. For this, small brush will be rubbed against the inside of the cheek.\n\nParticipants may have a computed tomography (CT) scan of the chest, abdomen, and pelvis. Or they may have a CT scan of the chest and magnetic resonance imaging (MRI) of the abdomen and pelvis.\n\nParticipants will be monitored every 6-12 months at the NIH Clinical Center, for up to 10 years before having surgery. If they need surgery, it will be performed at the NIH. Then, they will be monitored every 6-12 months, for up to 5 years after surgery.\n\nIf a participant has surgery, tumor tissue samples and research specimen will be taken.\n\nIf a participant does not need surgery, their participation will end after 10 years. If they have surgery, the 5-year monitoring period will restart after each surgery.",[82,83,84,85,26],"Gastric Cancer","Gastric Neoplasm","Gastrointestinal Stromal Sarcoma","Gastrointestinal Stromal Neoplasm",[87,88,89,90,91,92],"Tyrosine Kinase Inhibitor (TKI) Therapy","Wild-Type GISTs (WT GISTs)","PDGFRA Mutation","KIT Mutation","SDH Mutation","Natural History","2026-06-23",{"date":61,"type":32},{"date":96,"type":32},"2020-12-18",{"date":98,"type":19},"2040-12-30",{"name":100,"class":101},"National Cancer Institute (NCI)","NIH",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":52,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":126},"100331374","phase-1-a-study-of-hqp1351-in-patients-with-gist-or-other-solid-tumors-100331374","NCT03594422","A Study of HQP1351 in Patients With GIST or Other Solid Tumors","A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.","Inclusion Criteria:\n\n1. Male or not pregnant or lactating women, age≥12years.\n2. Advanced and\u002For metastatic GIST or other solid tumors, confirmed by histology and\u002For cytology. GIST patients must be primary resistant to imatinib (tumor progresses within 6 months first-line imatinib treatment, or succinate dehydrogenase B (SDHB) deficient confirmed by immunohistochemistry, or NF1 mutation), OR imatinib or imatinib and at least one other TKI treatment failure (after imatinib or other TKI treatment for more than 6 months, tumor progress again after achieving tumor remission or stability).\n3. ECOG≤ 2.\n4. Estimated survival at least 3 months.\n5. Adequate hematologic and bone marrow functions.\n6. Adequate renal and liver function.\n7. Heart function index:\n\n   * Troponin(I\u002FT) ≤ Upper Limit of Normal;\n   * Ejection fraction \\>40%;\n   * QTc interval ≤ 450 ms in male or ≤ 470 ms in female.\n8. Negative serum pregnancy test (for women of childbearing potential) documented within the 24-hour prior to the first dose of investigational product.\n9. Willing to use contraception by a method that is deemed effective by the investigator by Subject and their partners throughout the treatment period and for at least 30 days following the last dose of study drug.\n10. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the subject prior to any study-specific procedures).\n11. Willing and ability to comply with study procedures and follow-up examination.\n\nExclusion Criteria:\n\n1. Received any anti-cancer chemotherapy, biological agent treatment (e.g. Monoclonal antibody), immunotherapy (e.g. IFN) or radiotherapy with 28 days or 5 times half- time before first dose of HQP1351.\n2. Received any TKIs within 14 days before first dose of HQP1351.\n3. Attended any clinical trials on other drugs within 14 days before first dose of HQP1351.\n4. Have not recovered (\\> Grade 1 by CTCAE, v. 4.0) from AEs (except alopecia) due to agents previously administered.\n5. Malabsorption syndrome or other diseases that affect the absorption of oral drugs.\n6. Cardiovascular diseases of clinical significance, uncontrollable or active, including but not limited to: history of myocardial infarction; unstable history of angina pectoris; a history of congestive heart failure or lower left ventricular ejection fraction (LVEF) than normal limit within 6 months; the history of atrial arrhythmias was judged by the researchers to have important clinical significance; history of ventricular arrhythmias, etc.\n7. Hypertension was still poorly controlled after medication treatment (SBP \\> 140 mmHg and\u002For DBP \\> 90 mmHg).\n8. Concurrent use any medication led to prolong QT interval.\n9. Pulmonary mean arterial pressure\\>35 mmHg by ECHO.\n10. Significant severe cardiovascular conditions during previous TKI treatment.\n11. Uncontrollable hypertriglyceridemia.\n12. Performed major surgery (except for intravenous catheterization or bone marrow biopsy) within 14 days of first dose of HQP1351.\n13. Arterial thrombosis or embolism events such as cerebrovascular accident (including transient ischemic attack, TIA), or venous thrombosis events or pulmonary embolism within 6 months before the first dose of HQP1351 or deep vein thrombosis within 3 months before the first dose of HQP1351.\n14. Brain metastasis.\n15. Had other primary malignant tumors in the last three years (exception of the tumors being cured for 5 years or more, or complete removal of non-melanoma skin cancer or successful treatment of carcinoma in situ, or the controlled prostate cancer).\n16. Had active, symptomatic infections (including known infections of HIV, viral hepatitis (A, B, or C)). If there is no history of infection, screening is not required.\n17. Subjects who are known to be allergic to pharmaceutical ingredients or their analogs.\n18. Pregnancy or lactation, or expect to be pregnant during the study period.\n19. According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may jeopardize the safety or safety assessment of the subject.\n20. Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.","12 Years",{"count":51,"type":19},[112],"PHASE1","This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK\u002FPD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.",[26,115],"Solid Tumor, Adult","2026-04-06",{"date":118,"type":32},"2026-04-09",{"date":120,"type":32},"2018-07-11",{"date":122,"type":19},"2028-12",{"name":124,"class":125},"Ascentage Pharma Group Inc.","INDUSTRY",6,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":52,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100564519","phase-1-a-master-protocol-to-evaluate-dcc-3009-in-gastrointestinal-stromal-tumor-gist-100564519","NCT06630234","A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","A Master Protocol for the Multi-cohort, Open-label, Phase 1\u002F2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)","Inclusion Criteria:\n\nModule A Part 1 (Escalation):\n\n* Any participant with histologically or cytologically confirmed advanced\u002Funresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced\u002Fmetastatic setting\n* Have at least 1 measurable lesion as defined by mRECIST, v1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1\n* Adequate organ function, bone marrow function, and electrolytes\n* All participants agree to comply with the contraception requirements\n* Have a life expectancy of more than 3 months\n\nExclusion Criteria:\n\n* Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug\n* Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer\n* Has known active central nervous system (CNS) metastases or an active primary CNS cancer\n* History or presence of clinically relevant cardiovascular abnormalities\n* Major surgery within 28 days of the first dose of study drug\n* Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n* Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug\n* Known allergy or hypersensitivity to any component of the study drug\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Any other clinically significant comorbidities",{"count":135,"type":19},120,[112,137],"PHASE2","The purpose of this Phase 1\u002F2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.",[26],[141,142],"PDGFRA mutations","KIT mutations","2026-02-03",{"date":145,"type":32},"2026-02-05",{"date":147,"type":32},"2024-12-10",{"date":149,"type":19},"2028-05",{"name":151,"class":125},"Deciphera Pharmaceuticals, LLC",10,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":52,"phases":162,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":176},"100566443","phase-1-a-study-of-ziftomenib-in-combination-with-imatinib-in-patients-with-advanced-gastrointestinal-stromal-tumors-gist-100566443","NCT06655246","A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","A Phase 1a\u002F1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure","Key Inclusion Criteria:\n\n* Documented diagnosis of advanced\u002Fmetastatic KIT-mutant GIST.\n* Documented disease progression on imatinib as current or prior therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 at screening.\n* At least 1 measurable lesion per RECIST v1.1 modified for GIST.\n* Negative pregnancy test for participants of childbearing potential.\n* Adequate organ function per protocol requirements.\n* Resolution of all clinically significant toxicities from prior therapy to \\\u003CGrade 1 (or participant baseline) within 1 week before the first dose of study intervention.\n* Participant, or legally authorized representative, must be able to understand and provide written informed consent before the first screening procedure.\n\nKey Exclusion Criteria:\n\n* Diagnosis of GIST without a KIT mutation or with a T670X KIT mutation.\n* History of prior or current cancer that has potential to interfere with obtaining study results.\n* Received a prohibited medication, including investigational therapy, less than 14 days or within 5 drug half-lives before the first dose of study intervention.\n* Active central nervous system metastases.\n* Uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease.\n* Mean corrected QT interval (QTcF) greater than 470ms.\n* Left ventricular ejection fraction (LVEF) \\\u003C50%.\n* Major surgery within 2 weeks before the first dose of study intervention.\n* Is pregnant or breastfeeding.\n* Gastrointestinal abnormalities that may impact taking study intervention by mouth.\n* Actively bleeding, excluding hemorrhoidal or gum bleeding.",{"count":161,"type":19},157,[112],"In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.",[26,165,85,166,167],"Gastrointestinal Stromal Cancer","Gastrointestinal Stromal Tumor, Malignant","Gastrointestinal Stromal Cell Tumors",[169,165,85],"Gastrointestinal Stromal Tumor",{"date":145,"type":32},{"date":172,"type":32},"2025-03-27",{"date":122,"type":19},{"name":175,"class":125},"Kura Oncology, Inc.",32,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":40},"100136578","clinical--pathological-studies-of-upper-gastrointestinal-carcinoma-100136578","NCT01048281","Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma","Inclusion Criteria:\n\n1. Over 18\n2. Diagnosed with gastric or esophageal cancer OR at an increased hereditary risk for upper GI cancer\n\nExclusion Criteria:\n\n1. Under 18\n2. No family or personal history of gastric or esophageal cancer",{"count":51,"type":19},"Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood samples from upper gastrointestinal cancer patients and persons at high inherited risk for these cancers. We hope to learn the role genes and proteins play in the development of gastric and esophageal cancer.",[186,187,188,189,26],"Stomach Cancer","Gastro-Esophageal(GE) Junction Cancer","Gastric (Stomach) Cancer","Esophageal Cancer","2025-12-17",{"date":192,"type":32},"2025-12-18",{"date":194,"type":4},"2002-08",{"date":196,"type":19},"2099-01",{"name":198,"class":39},"Stanford University",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100601325","resistance-profiling-using-functional-imaging-and-next-generation-sequencing-in-refractory-gastrointestinal-stomal-tumors-gist-100601325","NCT07109024","Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)","Pilot Diagnostic Feasibility Trial of Resistance Profiling Using Functional Imaging and Next Generation Sequencing of Refractory GIST","PATHFINDERS","Inclusion Criteria:\n\n* Advanced gastrointestinal stromal tumors history of exposure and progression or intolerance to imatinib, sunitinib, regorafenib and ripretinib\n* Clinical indication for PET-CT and tumor biopsy (optional) (sarcoma center tumorboard protocol)\n* Age 18 years and older\n* FFPE tumor tissue available\n* Previous imaging studies available (CT\u002FMRI\u002FPET Abdomen, ideally at baseline, best response and progression)\n* ECOG ≤ 2\n* Progressing tumor lesion(s) of which one is accessible for biopsy\n\nExclusion Criteria:\n\n* contraindication for systemic TKI treatment\n* contraindication for contrast-enhanced both CT and MRI imaging.\n* GIST without KIT or PDGFRA mutations\n* pregnant or breastfeeding women\n* patient that - to the investigator's discretion - are not able or willing to comply with the provided protocol and visit schemes",{"count":208,"type":19},40,"Gastrointestinal stromal tumors (GIST) are the most common malignant sarcomas of the gastrointestinal tract. Inhibitors of the mutated driver proteins KIT and PDGFRA can temporarily control disseminated GIST disease but cannot cure it. Recently, the investigators were able to elucidate the two main resistance mechanisms-the coexistence of ATP-binding pocket (AP) and activation loop (AL) mutations, as well as AP\u002FAL combination mutations. Determining these resistance factors requires methods that are not yet established in routine clinical practice. The investigators hypothesize that identifying these factors and creating resistance profiles in the context of the anatomical location of metastatic lesions can open up new, clinically relevant therapeutic options, including local therapies. The aim of this project is to evaluate the practicability of these methods in everyday clinical use. An AI-supported image analysis and specialized molecular methods will be combined into a comprehensive resistance profile and will be provided to the treating physicians to potentially guide treatment decisions.",[26],[24,212,213,214,215],"Resistance","Ripretinib","Progression","Imaging","NOT_YET_RECRUITING","2025-08-13",{"date":219,"type":32},"2025-08-19",{"date":221,"type":19},"2025-09-01",{"date":223,"type":19},"2031-03",{"name":225,"class":39},"Universität Duisburg-Essen",2,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":40},"100601124","ceh-eus-for-differentiating-gists-and-leiomyomas-a-multicenter-prospective-self-controlled-study-100601124","NCT07106411","CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study","Contrast-Enhanced Harmonic Endoscopic Ultrasound for the Differential Diagnosis Between Gastrointestinal Stromal Tumors and Leiomyomas: A Multicenter Prospective Self-Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years and ≤ 85 years;\n* Subepithelial lesion in the gastrointestinal tract identified under white-light endoscopy and scheduled for CEH-EUS examination to determine the nature of the lesion;\n* EUS image quality meets the following quality control standards:\n\n  1. Equipment requirements: EU-ME2 processor (Olympus, Tokyo, Japan) and GF-UCT260 \u002F GF-UE260 echoendoscope (Olympus, Tokyo, Japan);\n  2. Image acquisition: Five EUS still images clearly displaying the lesion and surrounding structures, including maximum lesion diameter, originating layer, Doppler signals, and internal echo characteristics; a 15-second video clearly demonstrating the lesion without any artificial annotations (e.g., scale, needle, Doppler signal, elastography, etc.);\n  3. CEH-EUS procedure: Use of extended pure harmonic detection (Ex-PHD) mode with mechanical index (MI) adjusted to 0.3; 2.4 mL of SonoVue contrast agent is injected via the elbow vein within 2-3 seconds, followed by a 5 mL saline flush; real-time dynamic image acquisition continues for 120 seconds, and video recording is collected.\n* Patients with GIST confirmed by surgical or endoscopic resection pathology, and patients with leiomyoma confirmed by surgical resection, EUS-guided tissue sampling, or other biopsy techniques;\n* Written informed consent is obtained.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>85 years;\n* Hemoglobin level ≤8.0 g\u002FdL;\n* Known allergy or hypersensitivity to ultrasound contrast agents;\n* Pregnant women;\n* Severe cardiopulmonary dysfunction that precludes tolerance of endoscopic ultrasound examination;\n* Inability to provide written informed consent (e.g., due to psychiatric disorders or substance abuse).","85 Years",{"count":236,"type":19},288,"The investigators conduct a prospective, multicenter diagnostic trial primarily aimed at evaluating the value of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) in differentiating gastrointestinal stromal tumors (GISTs) from leiomyomas, as well as its predictive utility in the risk stratification of GISTs.",[239,26,240],"Submucosal Tumor","Leiomyoma",[242,243],"Endoscopic ultrasound","Contrast-Enhanced Ultrasonography","2025-07-30",{"date":246,"type":32},"2025-08-06",{"date":248,"type":19},"2025-08",{"date":250,"type":19},"2026-10",{"name":252,"class":39},"Huazhong University of Science and Technology",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":272,"leadSponsor":274,"locationsCount":40},"100598949","multicenter-observational-study-of-multimodal-ai-for-upper-gi-mesenchymal-tumor-diagnosis-100598949","NCT07078136","Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis","Multicenter Observational Study of a Multimodal AI Model Using EUS, White-Light Endoscopy, and Clinical Data for Diagnosis of Upper GI Mesenchymal Tumors and Risk Stratification of Gastric GISTs","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients with an upper gastrointestinal subepithelial lesion (SEL) identified by white-light endoscopy and who have completed an endoscopic ultrasound (EUS) examination\n* Patients with a histopathological diagnosis of GIST confirmed by surgical or endoscopic resection, or other SELs confirmed by surgical resection, EUS-guided sampling, or other biopsy techniques\n* EUS image quality meets the following quality control standards\n\n  1. Equipment requirements: Olympus EU-ME2\u002FME1 processor (Olympus Medical Systems Corp., Tokyo, Japan); radial EUS scope (GF-UE260\u002FGF-UE240; Olympus, Tokyo, Japan) or linear EUS scope (GF-UCT260\u002FGF-UCT240; Olympus, Tokyo, Japan); miniature probe (UM2R\u002F3R; Olympus, Tokyo, Japan); Pentax ARIETTA 850 processor (Pentax, Tokyo, Japan); radial EUS scope (EG-3670URK, Pentax, Tokyo, Japan); linear EUS scope (EG-3870UT, Pentax, Tokyo, Japan); Fujifilm SU-8000 or SU-9000 processor; linear EUS scope (EG-580UT, Fujifilm, Tokyo, Japan); radial EUS scope (EG-580UR, Fujifilm, Tokyo, Japan)\n  2. EUS images clearly showing the lesion and surrounding tissue characteristics (at least 5 images or video); must include at least one image of the maximum lesion diameter, one image showing the layer of origin, and one image demonstrating the growth pattern (intraluminal\u002Fextraluminal)\n  3. EUS images must not contain artificial annotations, such as measurement scales, biopsy needles, Doppler signals, or elastography overlays\n  4. Image resolution must be at least 448 × 448 pixels\n* WLE (white-light endoscopy) image quality meets the following standards: images must clearly show the lesion location, mucosal features, and margins; at least one close-up and one distant view\n* Complete clinical data and histopathological reports must be available\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Absolute contraindications for EUS examination, history of gastric surgery, pregnancy, severe comorbidities, or known allergy to anesthetic agents\n* EUS examination terminated prematurely due to esophageal stricture, obstruction, large space-occupying lesions, rapid changes in heart rate or respiratory rate, patient intolerance, or excessive residual food\n* EUS image quality does not meet the required quality control standards\n* Pathological specimens do not meet diagnostic requirements: insufficient biopsy tissue (only R0 resection specimens are accepted for the GIST group), or incomplete immunohistochemical staining (missing CD117\u002FCD34\u002FDOG-1 expression report for the GIST group)\n* Pathological results indicate that the lesion is a metastatic tumor originating from another site",{"count":261,"type":19},130,"This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.",[239,26,240,264],"Schwannoma",[266,242,267],"Artificial Intelligence","white-light endoscopy","2025-07-28",{"date":270,"type":32},"2025-07-31",{"date":268,"type":32},{"date":273,"type":19},"2026-06",{"name":252,"class":39},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":283,"maxAge":49,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":286,"conditions":287,"keywords":301,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":40},"100598488","an-international-study-on-pediatric-patients-with-rare-tumors-100598488","NCT07072143","An International Study on Pediatric Patients With Rare Tumors.","The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.","PARTNER","Inclusion Criteria:\n\n* Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and\u002For treated in a participating country\u002Fcenter.\n* Written informed consent from the patient and\u002For the parent\u002Flegal guardian\n\nExclusion Criteria:\n\n* Absence of Written informed consent from the patient and\u002For the parent\u002Flegal guardian","0 Years",{"count":285,"type":19},6250,"The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.",[288,289,26,290,291,292,293,294,295,296,297,298,299,300],"Paraganglioma\u002F Phaeochromocytoma","Melanoma and Other Malignant Neoplasms of Skin","Adrenocortical Tumor","Pancreatic Tumors","Esthesioneuroblastoma, Olfactory","Mesothelioma","Nasopharyngeal Carcinoma (NPC)","NUT Carcinoma","Pleuropulmonary Blastoma","Salivary Gland Tumors","Thymic Tumors","Thyroid Carcinoma","Appendiceal Cancers",[302,303,304,305,306],"children","rare tumors","very rare tumors","adolescents","PARTNER Study","2025-07-16",{"date":309,"type":32},"2025-07-18",{"date":311,"type":32},"2025-01-25",{"date":313,"type":19},"2049-06-06",{"name":315,"class":39},"Azienda Ospedaliera di Padova"]